International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 1 , Pages 35-41, 1 September 2010

Expression of Bcl-2, p53, and MDM2 in Localized Prostate Cancer With Respect to the Outcome of Radical Radiotherapy Dose Escalation

  • Roy Vergis, M.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Catherine M. Corbishley, M.D.

      Affiliations

    • Department of Cellular Pathology, St. George's Hospital, Tooting, UK
    • ,
  • Karen Thomas, B.Sc.

      Affiliations

    • Statistics, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Alan Horwich, M.D., Ph.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Robert Huddart, M.D., Ph.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Vincent Khoo, M.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Ros Eeles, M.D., Ph.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Matthew R. Sydes, B.Sc.

      Affiliations

    • Medical Research Council Clinical Trials Unit, London, UK
    • ,
  • Colin S. Cooper, Ph.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • David Dearnaley, M.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Chris Parker, M.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • Corresponding Author InformationReprint requests to: Dr. Chris Parker, M.D., Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. Tel: (+44) 0-020-8661-3425; Fax: (+44) 0-020-8643-8809

Received 7 April 2009; received in revised form 10 July 2009; accepted 16 July 2009. published online 20 January 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by the Institute of Cancer Research, the Cancer Research UK Section of Radiotherapy [CUK] grant number C46/A2131, the NCRI South of England Prostate Cancer Collaborative, and the Grand Charity of Freemasons. The authors acknowledge NHS funding to the NIHR Biomedical Research Centre. This work was undertaken in The Royal Marsden NHS Foundation Trust, which received a proportion of its funding from the NHS Executive; the views expressed in this publication are those of the authors and not necessarily those of the NHS Executive.

 Conflict of interest: none.

PII: S0360-3016(09)02921-6

doi:10.1016/j.ijrobp.2009.07.1728

International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 1 , Pages 35-41, 1 September 2010

Article Tools

* Image Usage & Resolution